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H I G H L I G H T S
• This systematic review provides information on LDLR, APOB, PCSK9 variants in Asia.• Among 8994 FH families in 48 Asian countries, 629 LDLR variants were reported.• Twenty variants were reported as the common variants in Asia.• The frequency and distribution of the variants were high in East Asia.








A B S T R A C T
Background and aims: Genetic identification is a public health care concern for management of familial hy-
percholesterolemia (FH) associated cardiovascular morbidity and mortality. This study presents the spectrum
and distribution of LDLR, APOB, PCSK9 gene mutations in Asia.
Methods: Databases were searched for English papers from 1950 to 2019. The spectrum of the variants was
investigated in 8994 FH families in 48 Asian countries. We determined the frequency of variants, zygosity, and
clinical features.
Results: Twenty countries have studied LDLR variants. A total of 629 mutations were reported and twenty
variants were accounted as common variants in different populations. China, Japan, India and Taiwan con-
stituted 68% of published articles. The most frequent mutation was reported in Japan but was not common in
other countries. Other missense variants accounted for 50% of the mutations, frameshifts 19%, and nonsense
11%. The pooled frequency of variation was estimated in 1867 individuals. Approximately 67% of Iranian
families were homozygous.,The common variant was p.Ser130Ter. p.Arg3527Trp in APOB was common among
184 heterozygous patients; the common variant of PCSK9 was p.Glu32Lys.
Conclusions: This is the first systematic review of LDLR, APOB, PCSK9 mutations in FH patients in Asia. These
findings underscore the need to fill in the gap of studies on different populations in Asia. It also underlies the
importance of early detection and management to decrease atherosclerosis and cardiovascular risk in different
ethnicities.
1. Introduction
Pathogenic variants of the LDLR gene, as the main cause of familial
hypercholesterolemia (FH, OMIM: #143890), lead to about two percent
of early myocardial infarction (MI) [1]. FH is one of the common lipid
disorders with an approximate prevalence of 1:250 [2]. It has auto-
somal dominant inheritance [3] although there is a low frequency of
autosomal recessive pattern with an estimated prevalence of 1 in
200,000 to 300,000 [4,5]. The frequency of FH varies among different
populations and a proportion of affected individuals remain un-
diagnosed [6]. There is no study about the prevalence of FH in Asia. It
seems that the prevalence may differ because of sociodemographic
characteristics.
FH has a wide spectrum of clinical symptoms, due to defects in
proteins involved in LDL uptake and catabolism [7], including the
proteins encoded by LDL-receptor (LDLR), apolipoprotein-B (APOB),
LDL receptor adaptor protein (LDLRAP1) and PCSK9 (PCSK9) [4]. More
than 90% of FH cases are due to pathogenic variants in the LDLR gene
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[8]. Pathogenic variants in LDLR lead to an abnormal increase in low-
density lipoprotein cholesterol (LDL-C) resulting in 5–8 times higher
risk of premature coronary artery disease (CAD) [9]. Xanthomas, pre-
mature and progressive atherosclerotic cardiovascular disease (ACVD)
are seen in the patients [8].
To date, approximately more than two thousands pathogenic var-
iants have been reported in LDLR in HGMD professional 2019 (http://
www.hgmd.cf.ac.uk), including different types of variants i.e. missense,
nonsense, large deletion, duplication, indel, regulatory and splicing
mutations. The type of variant could affect the degree of increased LDL
and cholesterol, severity of the disease and risk of CAD development
[10]. Different types of variants have been reported among various
Asian countries and we aim to investigate the distribution, frequency,
functional variants, zygosity, and clinical phenotype in Asia. Only the
developed Asian countries have a systematic review of the variants in
their population. The aim of this systematic review is to explore all
records of FH LDLR, APOB and PCSK9 mutations reported in databases
for Asia as the major genetic causes of monogenic FH. In patients with
no causative mutation, the polygenic cause is suggested, which is out of
the scope of this manuscript. In addition, the genotypic spectrum of the
Iranian population is studied and reported in this survey to add new
data on LDLR mutations to Asia.
2. Patients and methods
2.1. Search strategy
A systematic search was conducted on the Asian published articles
about familial hypercholesterolemia patients with LDLR, APOB and
PCSK9 pathogenic variants. All the English published articles in data-
bases (PubMed, Science Direct, John Wiley, Google Scholar) were
searched from 1950 to 2019 using the following keywords: LDLR [title]
gene mutations OR LDLR, AND familial hypercholesterolemia. LDLR
and name of each Asian country were specifically used to find all the
relevant articles, for example IRAN AND LDLR (Fig. 1). The MeSH term
for PubMed is available (Supplementary MeSH). Also, APOB and PCSK9
variants were searched using terms “PCSK9” AND “gene mutation”
AND “familial hypercholesterolemia” and “APOB” AND “gene muta-
tion” AND “familial hypercholesterolemia”.





The articles were selected according to the following inclusion cri-
teria: 1) original, cohort, cross sectional, case-control, case-report stu-
dies, 2) patients clinically diagnosed with FH having LDLR, APOB,
PCSK9 mutations and 3) patients with Asian ethnicity.
The non-English articles, congress abstracts, editorials, letters,
books, reviews, systematic reviews, non-Asian studies, in vitro and in
vivo studies, functional studies and pharmacogenomic studies, other
genes/mutations involved in FH were excluded; furthermore, articles
with insufficient data were not included in the study.
2.3. Data extraction
The accuracy and validity of the selected articles were reviewed by
investigators. The title and abstract of each article were reviewed in-
dependently considering inclusion criteria. Number of patients/fa-
milies, clinical significance of the variants, population, zygosity, low-
density lipoprotein cholesterol (LDL-C) level, total cholesterol (TC),
triglyceride (TG) level, high-density lipoprotein (HDL) level, nucleotide
and amino acid change and type of molecular technique were extracted
from the articles. Nomenclature for the description of sequence variants
was applied to all genetic entries according to the Human Genetic
Variation Society (HGVS) recommendations (http://varnomen.hgvs.
org/). Entries with unknown or uncorrected naming were removed or
corrected to ensure the adherence to HGVS. Also, authors were
Fig. 1. Study selection process including databases, number of articles, and final number of included articles. The relevant articles with LDLR mutations have been
available since 1970.
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contacted for additional information.
2.4. Quality assessment
The American College of Medical Genetics and Genomics (ACMG)
guideline was used to assess the quality of the variants [11]. The studies
were selected based on inclusion criteria. The studies enrolled were
selected based on Newcastle-Ottawa Scale (NOS) (http://www.ohri.ca/
programs/clinical_epidemiology/oxford.asp) to evaluate the quality of
data; studies rating ≥5 (out of 9) were selected for this study. Also,
quality assessment of variants was conducted by two investigators. The
quality of the studies was discussed between investigators and the final
decision was reached with consensus.
This systematic review was conducted following preferred reporting
items or systematic reviews and meta-analysis (PRISMA 2009) state-
ment.
2.5. Statistical analysis
Data were analyzed with the statistical Package for Social Sciences
(SPSS version 22.0, SPSS, Inc., Chicago, Ill, USA).
2.6. Study participants and molecular analysis of LDLR gene
The clinically diagnosed individuals with FH were referred to the
genetic laboratory. Biochemical characteristics such as TC, HDL, LDL-C,
and TG were reordered for each patient. After obtaining signed in-
formed consent, genetic testing was performed for 37 cases clinically
diagnosed with FH. The methods used for patients are in accordance
with the genetic testing guidelines for familial hypercholesterolemia
and all experimental protocols were approved by the Rajaie
Cardiovascular Medical and Research Center.
2.7. In silico analysis
The gene reference sequence NG_009060, NM_000527.4 was used to
determine the variant position. Position of the variants in protein was
determined based on UniProtKB/SwissProt P01130. The functional ef-
fect of each variant was predicted based on amino acid domains and
regions of LDL-R protein.
2.8. Ethical approval
The experimental protocols are approved by Rajaie Cardiovascular




The search strategy yielded 14,003 articles since 1970. Duplicates
were removed and 1925 articles remained. These articles were re-
viewed according to inclusion and exclusion criteria. 1458 articles re-
mained only based on title and abstract; 1000 articles were excluded
after review of published literature considering the criteria. After data
extraction, 160 eligible articles were included in our systematic analysis
(Fig. 1). Any entry that could not be verified was deleted from this
study.
Among 48 different countries in Asia, 20 countries published arti-
cles on LDLR mutations. China, Japan, India and Taiwan constituted
68% of published articles (Table 1 and Supplementary Tables S1, S6,
S7, S8). 8994 families were investigated in the Asian population
(Table 1). Japan and China represented 19% and 27% of the publica-
tions, respectively. A total of 629 mutations were reported from Asian
ethnicities (Supplementary Tables).
The clinical phenotype and biochemical assays such as TC, TG, LDL-
C, and HDL for each population and variant were extracted from pub-
lications (Supplementary Tables). The clinical phenotype of the study
varied including 196 xanthomas, 152 CAD, 32 MI, 10 angina, 35 cor-
neal arcus and others (17) were defined as cardiovascular diseases. The
mean TC and LDL-C level for each population was determined
(Table 2). Mean TC was> 7.9 mmol/L and mean LDL-C was> 5 for
heterozygotes in different populations. All the studies had LDL-C le-
vels> 13 mmol/L for homozygotes except Taiwanese (8.4 mmol/L)
and Arabians (12.4 mmol/L) (Table 2). Accordingly, the homozygous
genotypes had higher LDL-C levels than heterozygous patients.
The variants were counted based on the number of variants in dif-
ferent published articles; 27 mutations were distributed sequentially
along the Asian countries based on frequently published variants
(Supplementary Tables).
Accordingly, the variants were 312 missenses (50%), 67 nonsenses
(11%), 119 frameshifts (19%), 46 copy number variations (small and
large deletions) (7%), and 56 splicing (9%) variants. Also, synonymous
substitutions accounted for 11 of 629 variants with unknown patho-
genicity. Nonsense and frameshift variants were predicted as loss of
function variants, pathogenic/likely pathogenic variants; this included
37% of the variants. Splicing (9%) and regulatory variants (4%) were
predicted to cause haploinsufficiency. Also, missense variants may
cause haploinsufficiency; as we cannot predict the functional effect of
the missense variant unless in vitro analysis is performed to confirm the
effect.
The distribution of the LDLR variants in Asia included 202 (40%)
ligand binding site class A, 165 (33%) ligand binding site class B, 92
(18%) epidermal growth factor domain, 13 of 507 O-linked sugar do-
main, and transmembrane and cytoplasmic domains.
Different methods of detection of the variants have been used for
genetic analysis of FH in different populations (Supplementary Tables).
31% of the variants (50 of 160) were investigated only by direct se-
quencing in the population. NGS and targeted exome sequencing was
used in 11 of 160 (7%) of the studied publications. Furthermore, 62% of
mutations were analyzed by combination of genetic techniques e.g.
RFLP and Sanger sequencing.
The zygosity was determined for the defined number of individuals
in different populations (Table 2). The frequency of the variants in
various populations was investigated and frequent variants were de-
termined for each as indicated below.
3.2. LDLR mutations in South East Asia
In total, 8 articles were found in which 54 different mutations were
determined (Table 1 and Supplementary Table S9). A high number of
articles were published from Thailand in comparison to other countries
of this region; Singapore had 77% heterozygosity rate among South
East Asian countries (Table 2 and Supplementary Table S9). Only two
homozygous variants were reported from Vietnam. Malaysia had 9
Table 1
Published articles, number of families, reported LDLR variants in Asian coun-
tries according to search strategy.
Asia regionsa Publications Families Variants
North and South East 8 658 54
South 15 357 51
East 90 5476 496
West 21 672 40
Central 0 0 0




Total 160 8994 629 (non-duplicate
variants)
a The classification of Asian regions in shown is Supplementary Data.
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Table 2
The biochemical analysis of patients in different Asian populations. Heterozygote, homozygote, compound heterozygote distribution among countries.
Country (no of cases) Number of individuals with available biochemical data Total cholesterol (mmol/L) Triglycerides (mmol/L) LDL-C (mmol/L) HDL-C (mmol/L)
North and South East Asia
Thailand (2) 2 10.2 2.6 8.2 1.4
Het (2) 2 10.2 2.6 8.2 1.4
Malaysia (164) 164 7.9 1.9 5 1.3
Het (43) NA NA NA NA NA
Singapore (56) 50 8.5 1.2 6.7 1.4
Het (51) 50 8.5 1.2 6.7 1.4
Hom (5) NA NA NA NA NA
Vietnam (4) 4 18.4 NA 16.2 NA
Hom (4) 4 18.4 NA 16.2 NA
South Asia
Pakistan (5) 5 15.4 1.0 12.3 1.1
Het (5) 5 15.4 1.0 12.3 1.1
India (31) 19 14.6 2.9 12.2 1.04
CH (3) 3 18.1 1.5 16.4 0.6
Het (16) 6 8.2 5.2 5.2 1.2
Hom (12) 10 17.4 2.2 15.1 1.1
Sri Lanka (4) 4 10.9 NA 7.7 NA
CH (1) 1 13 NA 10.8 NA
Het (3) 3 9.4 NA 6.98 NA
East
China (513) 177 13.01 1.4 11.4 1.2
CH (91) 69 11.01 1.3 8.7 1.2
Het (134) 63 9.42 1.6 8.2 1.1
Hom (70) 45 16.5 1.3 13.6 1.3
(218)a 218 13.2 1.3 11.03 1.5
Japan (797) 122 14.21 1.8 11.65 1.3
CH (30) 28 15.3 1.5 13.22 0.97
Het (719) 46 9.95 1.72 7.58 1.40
Hom (48) 48 17.4 2.24 14.14 1.49
a Unknown 8.08 1.50 6.95 0.74
Korea (106) 94 8.54 1.7 6.15 1.45
Het (38) 38 8.98 1.6 7.4 0.9
Taiwan (721) 48 12.5 1.25 9.44 1.1
CH (23) 15 15.9 NA 12.98 1.15
Het (271) 31 10.6 1.3 8.02 1.3
Hom (3) 2 16.5 1.2 8.4 0.8
(440)a 440 8.98 1.46 6.54 1.39
West
Lebanon (133) – NA NA 11.5 NA
CH (0) 0 – – – –
Het (121) 15 NA NA 8.2 NA
Hom (62) 19 NA NA 14.0 NA
Arabb (17) 17 15.1 1.2 12.1 0.9
CH (1) 1 21.3 2.5 18 0.9
Het (4) 4 8.8 1.8 7.1 0.96
Hom (12) 12 15.2 1.1 12.4 0.8
Iran (135)
Het (1) 0 – – – –
Hom (9) 9 18.4 ± 4.6 NA 13.6 ± 3.8 NA
a 125 8.5 1.4 5.2 1.3
Het (6) 6 9.3 1.33 6.29 1.46
Hom (12) 12 15.4 1.92 13.2 1.49
Total mean (18) 18 13.3 1.73 10.89 1.48
Israel (103)
CH (1) 1 12.7 NA 11.4 0.9
Het (102) 20 7.99 1.7 5.9 1.2
Hom (0) 0 – – – –
Multi-ethnicity (247) 30 9.8 1.3 7.05 1.7
CH (1) 1 NA NA NA NA
Het (27) 27 9.5 1.3 7.1 1.7
Hom (2) 2 18.3 NA NA NA
Turkey (32) 32 13.9 1.2 11.4 1.3
CH (5) 5 15.4 1.02 12.3 1.1
Het (12) 12 8.02 1.4 5.8 1.3
Hom (15) 15 18.1 0.98 15.6 1.4
Russia (42) 42 10.8 12.5 8.99 1.2
CH (3) 2 11.7 1.06 9.7 1.6
Het (39) 27 10.8 1.7 8.96 1.9
Hom (0) 0 – – – –
Hom: homozygote, Het: heterozygote, CH: compound heterozygote, NA: not available.
a Publications including only biochemical assays and total mean biochemical assays.
b Arab including Saudi Arabia and Oman.
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variants in 43 patients with the heterozygosity rate of 26% (Table 2 and
Supplementary Table S10). The frequent variants in this geographical
region were c.301G > A (p.Glu101Lys, 11 of 43), c.763T > A
(p.Cys255Ser, 10 of 43) and c.601G > A (p.Glu201Lys, 9 of 43) in
Malaysia (Supplementary Table S9E). 43 variants were found in Sin-
gapore with the missense variant c.1747C > T (p.His583Tyr, 9 out of
66) being frequent (Supplementary Table S9F). Vietnam and Philippine
had no frequent variants.
Biochemical assays were used for variants and patients in each
population. The clinical phenotype was determined for some patients
(Supplementary Tables S9E and F).
3.3. LDLR mutations in South and Central Asia
Eight countries located in South Asia. Four countries published ar-
ticles on LDLR mutated FH patients. Overall, 51 mutations were found
in South Asian countries. India had ten (47%) published articles, and 39
unique variants (Supplementary Table S4). No relevant published ar-
ticles were found in Central Asia.
India had a 39% homozygosity rate (Table 2). No frequent variant
was found for India, Sri Lanka and Pakistan (Table 3 and
Supplementary Table S4A, S3 and S9). Clinical phenotype and bio-
chemical assays were determined for the population of these regions
(Table 2, Supplementary Tables S4B, S3, and S9D).
3.4. LDLR mutations in West Asia
In 9 out of 13 West Asian countries, no article on LDLR gene analysis
was found. 33 different mutations in LDLR were found in the remaining
countries. Ten mutations were reported in Saudi Arabia and 1 mutation
in Oman (c.272delG) (Supplementary Table S5). Iran and Lebanon each
published 4 articles and had 10 and 17 different mutations, respectively
(Supplementary Table S9). Three articles were found in Israel and 34
mutations were found in these studies.
The homozygosity rate was high in Lebanese 34%, and Arabians
70%. The heterozygosity was high in Israel (Table 2).
The frequent variants investigated were as follows: c.1729T > C
(p.Trp577Arg, 3 of 10) in Iran, c.2027delG (p.Gly676Alafs*33, 7 of 17)
in Arabia, c.del197 (p.Val66Hisfs*63, 35 of 103 (34%)) in Israel, and
c.2043C > A (p.Cys681Ter, 103 of 183) and c.1171G > A
(p.Ala391Thr, 10 cases) in Lebanon (Supplementary Tables S9 and
S9B). The heterozygosity rate of c.2043C > A (p.Cys681Ter) variant
was 56%, known as Lebanese allele. Its frequency was 21% in Israel, its
neighboring country (Table 2).
The clinical phenotype and lipid profile were identified for each
study (Supplementary Table, S5B, S9B, C and G).
3.5. LDLR mutations in East Asia
Our data revealed 408 mutations in East Asia, which accounted for
65% of the total reported mutations. Our study showed that frequent
mutations were mainly located in East Asia, because the main pub-
lications are reported in this region (Table 1).
Japanese studies showed 172 variants in 797 cases. 719 (90%) were
heterozygotes; homozygotes accounted for 48 (6%) variants. Totally,
346 variants were found in this population. The frequent mutations in
Japan were c.2431A > T (p.Lys790Ter), 2312-3C > A,
c.1845+2T > C, c.1012T > A (p.Cys338Arg), and c.1297G > C
(p.Asp433His) accounted for 241 (30%), 47 (6%), 32 (4%), 26 (3%)
and 21 (3%) variants, respectively (Supplementary Table S6A).
295 cases, including 134 heterozygotes, 70 homozygotes and 91
compound heterozygotes, were found in the Chinese population.
Totally, 177 mutations were found in the Chinese population. The
frequent variant is c.1448G > A in China (Tables 2 and 3, and
Supplementary Table S1A).
271 out of 297 cases were heterozygotes in Taiwan (Supplementary
Tables S8A and B). 81 variants were detected in this population, in
which 1747C > T (p.His583Tyr) was the frequent variant (Table- 3).
The heterozygosity rate in Korea was 36%. Among 50 variants,
c.661G > A (10%) was the frequent variant in Korea (Supplementary
Table S7A).
The clinical and biochemical assays are indicated for each popula-
tion (Supplementary Tables S1B, S6B, S7B, S8B).
3.6. LDLR mutations in patients with multi-ethnicity
Among 160 published articles, 10 articles enrolled patients from at
least two different ethnicities. Despite a few numbers of studies (10
articles), 121 different mutations were reported among these patients,
which accounted for 19% of total reported mutations (Supplementary
Tables S10A and B). Among the 30 individuals, 2 were homozygotes, 1
compound heterozygote and 27 heterozygotes (Table 2).
3.7. LDLR mutations in transcontinental countries (Turkey, Russia, Cyprus)
Turkey is a country located mainly in Western Asia. This study
showed that 7 articles have been published in Turkey; 28 different
mutations were determined in this region. Russia is another transcon-
tinental country in the Northern part of Asia. We identified 39 muta-
tions in patients with Russian ethnicity (Table 1 and Supplementary
Tables S2 and S9). Our search strategy revealed one study in Cyprus. 4
different mutations were determined in the Cyprus study
(Supplementary Table S9).
15 of 32 individuals were homozygotes and 12 were heterozygotes
in Turkey. The frequent variant was c.1729T > C (p.Trp577Arg) in
Turkey and c.2479G > A (p.Val827Ile) in Russia (Supplementary
Table S2A and B, S9A and H). The frequent variant was c.190+4A >
T, found in 3 cases in Cyprus (Supplementary Table S9D).
3.8. Common variants in Asia
The frequency of the variants was determined for each population.
The common variants were identified between the neighboring popu-
lations and other Asian countries (Table 3).
The common variants were c.301G > A (p.Glu101Lys) in Malaysia,
c.1747C > T (p.His583Tyr) in Singapore, c.2043C > A
(p.Cys681Ter) in Lebanon and Israel. The variant c.1171G > A
(p.Ala391Thr) in Lebanon was also seen in Malaysia and China.
c.1729T > C (p.Trp577Arg) was also common between Iran and
Turkey (Table 3).
43 of 797 cases had c.2054C > T (p.Pro685Leu) change in Japan,
which was also seen in China (9 of 295), Korea (7 of 38), and Taiwan (2
of 297). China had 1448G > A (p.Trp483Ter) in 36 of 295 (12%)
individuals of the population seen in Taiwan. 41 of 297 (14%)
Taiwanese had c.1747C > T (p.His583Tyr) mutation, which ac-
counted for 6% of patients in the Chinese population and 16% in the
Singapore population (Table 3).
3.9. APOB and PCSK9 mutations in Asia
Our study showed 20 studies in Asia with 41 APOB variants after
duplicate removal (Supplementary Table S10). 184 heterozygous in-
dividuals carrying APOB variants were detected and no homozygous
variant was found. APOB gene included 58 variants in Taiwanese, 47 in
Chinese, 27 in Vietnamese, 17 in Arabs and the rest were found in
Singapore, Korea, Israel, and Japan. The most common variant of APOB
was p.Arg3527Trp, accounting for 78 of 184 heterozygous variants. Of
course, 27 Vietnamese carried p.Arg3527Trp and 40 cases carried this
variant in Taiwanese (Supplementary Table S10).
20 variants of PCSK9 were found in 18 studies. Totally, 160 patients
were found including 117 heterozygotes and 43 homozygotes
(Supplementary Table S11). The most common variant was p.Glu32Lys
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in the Asian population seen in Japan.
To note, there is lack of information from most of the countries in
Asia and further investigation is needed to draw a conclusion about the
frequency of these variants in FH.
3.10. Genetic testing in the Iranian population
Molecular analysis of 37 patients determined 18 variants in the
studied cases. Seven novel variants were reported in our studied po-
pulation. The variants included seven missense mutations, 5 nonsenses,
4 frameshifts (2 deletions and 2 insertions) and two splicing variants.
Twelve were homozygotes and 6 variants were heterozygotes
(Supplementary Table S14). Therefore, 12 of 18 had LOF, known as
“negative LDLR”. Two splicing variants were homozygote; four mis-
sense variants were also homozygous; in addition, two termination
variants were heterozygotes, but we predicted them as “defective
LDLR” because of functioning in a multi complex receptor
(Supplementary Table S14).p.Ser130Ter was common in this study.
Two nonsense heterozygous variants were defined as pathogenic. The
splicing variant at intron 15 was determined in one case. Previous re-
ports have shown c.2312–2A > C mutation that causes alternative
splicing and results in deletion of exon 16 [27] (Supplementary Table
S14).
3.11. Genotype-phenotype correlation
Biochemical characteristics of each patient in the Iranian population
were determined (Supplementary Table S14 and Table 3); their relation
to the genotype was investigated. The mean age of the patients with
known genotype is 31.1 ± 14.02 years; with mean plasma cholesterol
level of 516.5 mg/dL (13.3 mmol/L). The mean LDL-C value of the
patients was 421.3 mg/dL (10.9 mmol/L), the mean high density li-
poprotein (HDL) value 57.2 mg/dL (1.5 mmol/L), and mean trigly-
ceride (TG) 153.7 mg/dL (1.7 mmol/L) (Table 2).
The mean cholesterol level for homozygous patients was
595.17 mg/dL (15.4 mmol/L) and LDL-C value was 510.17 mg/dL
(13.2 mmol/L), mean HDL 57.83 mg/dL (1.5 mmol/L) and mean TG
171.33 mg/dL (1.9 mmol/L). The mean criteria of FH diagnosis was
higher in homozygous in comparison to the total values (Table 2).
The heterozygous variants having termination effect on receptor
had low LDL-C (210 and 140 mg/dL) and (total cholesterol) TC values
(320 and 206 mg/dL). Therefore, these are suggested to cause an LDL
defective receptor. Similarly, it is concluded that the other four het-
erozygotes may cause LDL defective receptor having haploinsufficiency
(Supplementary Table S14).
4. Discussion
To the best of our knowledge, this is the first systematic review of
LDLR, APOB, PCSK9-related FH patients within Asian countries. To
date, only few systematic reviews were conducted on the LDLR gene
mutations in China, Arabic and Latin American countries [28–30]. We
gathered and analyzed a comprehensive panel and geographical dis-
tribution of mutations in monogenic FH patients reported in Asian
countries. The polygenic influence of the mutations in HeHF was not
studied in this systematic review.
Briefly, in our systematic review 629 variants among 8994 families
were recorded from 20 countries. Approximately, 42% of the Asian
countries did not have any information about FH.
The quality of variants was based on ACMG and pathogenic variants
were selected as genetic diagnostic factors for FH. Estimation of the
clinical phenotype, zygosity, functional variants and frequency of the
variants was included based on the reported participants in each
country and any bias may be caused by errors in clinical diagnosis,
reporting variants, outcome measurement, and statistical analysis of the
study.
Our results indicated that there is a significant genetic heterogeneity
among FH affected patients. Missense mutations accounted for ap-
proximately 50% of the variants. CNV (deletions, large duplications,
large deletions) accounted for 46 of 629 (7%) of the reported variants in
Asia. To explain, copy number variants account for> 10% of patho-
genic variants in founder mutations [31]. Therefore, for diagnostic
purpose, CNV analysis should be considered for genetic testing not to
miss any causal variant.
Only< 15% of the LDLR variant pathogenicity has been function-
ally analyzed in vitro [32]. Functional analysis from literature and
prediction analysis of the variants (online database) revealed that 326
of 629 pathogenic/probably pathogenic variants in LDLR gene are
present. Of course, 30% (186 of 629) are nonsense and frameshift
variants. It is assumed that nonsense, frameshift variants, and CNVs
cause truncated LDL receptor and are pathogenic. They produce no
protein or non functional receptors and are categorized as “receptor-
negative”. Missense variants are predicted to cause both “receptor-ne-
gative” and “receptor defective” proteins. Therefore, careful inter-
pretation of the results is needed; also functional studies provide in-
formation about the pathogenicity. The presence of false positive and
false negative reports may be obvious in this systematic review. Among
the reported variants, 73% were located at the ligand binding domain.
The twenty seven mostly reported variants were investigated in the
LDLR gene (Supplementary Table S11). The first ones are p.Pro685Leu,
p.His583Tyr, and p.Trp483Ter (Supplementary Table S11). In com-
parison, they were also common in the Chinese population [28]. In
addition, Arabic studies demonstrated that among these 27 frequent
mutations c.2043C > A (p.Cys681Ter) was frequent mainly in Le-
banon [29]. Variant p.Cys681Ter, known as Lebanese mutation, iden-
tified in 1987 by Lehrman, accounts for 82% and 45% of HeFH and
HoFH Lebanese patients, respectively [33].
Twenty common variants were determined in the LDLR gene in
Asia, and the distribution was shown in other countries. The frequency
of the variants was higher among neighboring countries (Table 3).
Some variants have a higher frequency in one specific region due to the
founder effect. For instance, p.Pro685Leu is the most common variant
in Eastern Asia. Likewise, p.His583Tyr is common in Taiwan, China,
Korea and Singapore, which may reflect immigration among these
countries. In the same way, the APOB and PCSK9 common variants
show the same pattern.
We have included genotypic data in the Iranian population due to
the fact that some of our variants reported for the first time can com-
plete the list of LDLR mutations reported worldwide and in Asia.
Interestingly, our investigation revealed a high frequency of LDLR gene
homozygosity (67%) in this population in comparison to other studies.
These differences are the consequence of consanguineous marriages.
Other patients may have variants in other genes or have a polygenic
basis of the disease, which should be investigated in future studies. The
French Canadian Québec population, Lebanese, South Africans have
higher homozygous frequency due to isolation and consanguineous
marriages. A genetic drift may occurred in the Quebec population [34].
Notably, HoFH patients with LDLR negative (< 2% activity) have
higher LDL-C level than LDLR defective (2–25% activity) patients [7].
Homozygous variants in the studied patients have higher mean LDL-C
13.2 mmol/L (510 mg/dL) value and the mean cholesterol level of
15.4 mmol/L (595 mg/dL). TG is also higher in homozygous
(1.9 mmol/L or 173 mg/dL) compared to all (1.7 mmol/L or 153 mg/
dL). This is also true in other Asian countries and the mean LDL-C level
of homozygous patients is > 13 mmol/L in comparison to the guide-
lines. The zygosity analysis shows correlation to the severity of the
phenotype and LDL-C level (Table 2).
Increased LDL-C levels in FH patients are due to impaired LDL-re-
ceptor activity, which is caused by different classes of LDLR mutations.
This study brings information about the reported variants of the studied
populations in Asia. According to the ACMG guidelines and the ex-
tracted Asian variants, 46% are annotated as pathogenic/probably
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pathogenic. The problem is that there are variants with unknown sig-
nificance of pathogenicity for which in vitro analysis or family studies
are required to define the variant. Population based reports of the
variants may give geneticists and clinicians clues about the influence of
the variants.
Our study limitations include restriction of other language usage
and data extraction from non-English published cohort studies con-
ducted in Asian countries. Those articles not having the search terms
would have been missed through the data extraction step. Besides, data
from some of the published articles were insufficient for data extraction
e.g. biochemical assays, and zygosity. The clinical data were not
available for all the studies, so we could not find out about the genotype
and phenotype correlation of the variants. The distribution of the var-
iants could not be investigated because there were not enough sampling
studies. The frequency and prevalence of variants are not defined due to
the lack of information in some publications. If more large-scale studies
are performed, genotype and phenotype could be determined in Asia.
To note, the pathogenicity of the variants was based on in silico analysis,
and functional analysis is needed to determine the functional influence
of missense variants.
In conclusion, this is the first systematic review of LDLR mutations
in FH patients in Asia. The identified variants provide a valuable source
for physicians and researchers in this part of the world. Although, the
Western part of Asia has limited studies, we encourage research to in-
vestigate FH in this part of Asia. This study provides information for
health care system providers to be aware of the signs and diagnosis of
FH and benefit from early treatment in Asia. Unraveling common var-
iants in each country could prioritize cost benefit diagnostic programs
and future probable therapeutic strategies. Furthermore, a specific
lifestyle could help patients with early diagnosis provided by cascade
screening.
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